Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with p...
Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Guselkumab is an anti‐interleukin‐23 human monoclonal antibody effective in treating psoriatic arthritis (PsA). To characterize the pharmacokinetics (PKs) and exposure‐response relationship of guselkumab in PsA, population PKs, and exposure‐response modeling, analyses were conducted using data from pivotal phase III studies of subcutaneous guselkum...
Alternative Titles
Full title
Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3046e99fbe70497397caa0fe05e2128d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3046e99fbe70497397caa0fe05e2128d
Other Identifiers
ISSN
1752-8054
E-ISSN
1752-8062
DOI
10.1111/cts.13197
